MSc (Health Services Research)

PhD (Health Economics)

Health Economist, Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital Vancouver

School of Population and Public Health, University of British Columbia

Nick Bansback recently completed his PhD in health economics and decision sciences at the University of Sheffield, UK under the supervision of Dr John Brazier. He is a health economist at the Centre for Health Evaluation and Outcome Sciences at St Paul's Hospital Vancouver working with Dr Aslam Anis.

Nick's work focuses on informing decisions in health, with much of his work in the area of arthritis. He has developed a number of economic evaluations to inform policy making on new treatment strategies in Rheumatoid Arthritis. His other work focuses on developing methods for valuing health benefits and harms.

Recent NDB research Recent NDB research

Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M, Sizto S, Liang MH. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009;151(9):612. PubMed link
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis & Rheumatism. 2008;58(4):939-46. PubMed link
Additional Information: 

Relevant publications:

 1. Finckh A, Bansback N, Marra CA, Michaud K, et al. Treatment of very early
    rheumatoid arthritis with symptomatic therapy, disease-modifying
    antirheumatic drugs, or biologic agents: a cost-effectiveness
    analysis.Ann. Intern. Med. 2009;151(9):612-621.
 2. Nixon RM, Bansback N, Stevens JW, Brennan A, Madan J. Using
    short-term evidence to predict six-month outcomes in clinical
    trials of signs and symptoms in rheumatoid arthritis. Pharm Stat.
    2009;8(2):150-162.
 3. Bansback N, Ara R, Ward S, Anis A, Choi HK. Statin therapy in
    rheumatoid arthritis: a cost-effectiveness and
    value-of-information analysis. Pharmacoeconomics. 2009;27(1):25-37.
 4. Bansback N, Harrison M, Brazier J, et al. Health state utility
    values: A description of their development and application for
    rheumatic diseases. Arthritis Rheum. 2008;59(7):1018-1026.
 5. Wailoo AJ, Bansback N, Brennan A, Wolfe F, Michaud K, et al. Biologic Drugs for
    Rheumatoid Arthritis in the Medicare Program. Arthritis Rheum.
    2008;58(4):939-946.
 6. Bansback N, Marra C, Tsuchiya A, et al. Using the health
    assessment questionnaire to estimate preference-based single
    indices in patients with rheumatoid arthritis. Arthritis Rheum.
    2007;57(6):963-71.
 7. Bansback N, Young A, Brennan A, Dixey J. A prognostic model for
    functional outcome in early rheumatoid arthritis. J
    Rheumatol.2006;33(8):1503-10.